# EDGAR Filing Document

**Accession Number:** 0001582313
**File Stem:** 0000950170-23-006719
**Filing Date:** 2023-3
**Character Count:** 6058
**Document Hash:** f99fc6c1f79f4383270bcbb83b6f1e3d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-006719.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0000950170-23-006719

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230308

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Xenon Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001582313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 980661854
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36687
- **FILM NUMBER:** 23716443

**BUSINESS ADDRESS:**
- **STREET 1:** 200 - 3650 GILMORE WAY
- **CITY:** BURNABY
- **STATE:** A1
- **ZIP:** V5G 48W
- **BUSINESS PHONE:** (604) 484-3300

**MAIL ADDRESS:**
- **STREET 1:** 200 - 3650 GILMORE WAY
- **CITY:** BURNABY
- **STATE:** A1
- **ZIP:** V5G 48W

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** March 8, 2023

------

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

------

---

| | | |
|:---|:---|:---|
| Canada | 001-36687 | 98-0661854 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 200-3650 Gilmore Way<br>Burnaby**,** British Columbia**,** Canada |  | V5G 4W8 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (**604**)** 484-3300

**Not Applicable** 

**(Former name or former address, if changed since last report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Shares, without par value | XENE | The Nasdaq Stock Market LLC<br>(The Nasdaq Global Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | &nbsp;&nbsp;&nbsp;**Other Events** |

---

On March 8, 2023, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2023 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.

---

| | |
|:---|:---|
| **Item 9.01** | &nbsp;&nbsp;&nbsp;**Financial Statements and Exhibits** |

---

(d) Exhibits.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description</u>** |
| 99.1 | [<u>SEDAR filing submitted March 8, 2023</u>](xene-ex99_1.htm). |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **XENON PHARMACEUTICALS INC.** | **XENON PHARMACEUTICALS INC.** |
| Date: March 8, 2023 | By: | /s/ Sherry Aulin |
|  |  | Sherry Aulin |
|  |  | Chief Financial Officer  |

---

------

## Ex-99

![img189401473_0.jpg](img189401473_0.jpg)

**Exhibit 99.1**

March 8, 2023

---

| |
|:---|
| Alberta Securities Commission |
| British Columbia Securities Commission |
| Ontario Securities Commission |

---

**RE: Xenon Pharmaceuticals Inc.**

Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:

---

| | |
|:---|:---|
| Date of meeting: | June 1, 2023 |
| Record date for notice: | April 4, 2023 |
| Record date for voting: | April 4, 2023 |
| Beneficial ownership determination date: | April 4, 2023 |
| Securities entitled to notice: | Common Shares |
| Securities entitled to vote: | Common Shares |
| Issuer mailing directly to non objecting beneficial owners: | No |
| Issuer will pay for objecting beneficial owner material distribution: | Yes |
| Issuer using notice-and-access for registered investors: | No |
| Issuer using notice-and-access for non-registered investors: | No |
| Notice-and-access stratification criteria: | N/A |

---

Yours very truly,

/s/ John Lundberg

John Lundberg

Senior Relationship Manager

American Stock Transfer & Trust Company, LLC

------